A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Running, not enrolling · Phase 2
Conditions studied: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
In brief
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Key facts
- Study ID
- NCT05635708
- Run by
- BeiGene
- People needed
- 400
- Starts
- 2023-03-07
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-04-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York, United States
- Providence Portland Medical Center — Portland, Oregon, United States
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States
- Blacktown Cancer and Haematology Centre — Blacktown, New South Wales, Australia
- Chris Obrien Lifehouse — Camperdown, New South Wales, Australia
- Northern Beaches Hospital — Frenchs Forest, New South Wales, Australia
- Port Macquarie Base Hospital — Port Macquarie, New South Wales, Australia
- One Clinical Research — Nedlands, Western Australia, Australia
- St John of God Health Care — Subiaco, Western Australia, Australia
- Hospital de Amor Barretos — Barretos, Brazil
- Hospital Do Cancer de Londrina — Londrina, Brazil
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus — Porto Alegre, Brazil
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto — São José do Rio Preto, Brazil
- Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira — São Paulo, Brazil
- Cross Cancer Institute — Edmonton, Alberta, Canada
- The Second Hospital of Anhui Medical University — Hefei, Anhui, China
- The Fifth Medical Center of Chinese Pla General Hospital — Beijing, Beijing Municipality, China
- Fujian Cancer Hospital — Fuzhou, Fujian, China
- Affiliated Hospital of Hebei University — Baoding, Hebei, China
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
- Henan Cancer Hospital — Zhengzhou, Henan, China
- Hubei Cancer Hospital — Wuhan, Hubei, China
- Nantong Tumor Hospital Branch North — Nantong, Jiangsu, China
- Valkyrie Clinical Trials — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.